Kiora Pharmaceuticals Inc (KPRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.44M
Last updated: Nov 17, 2026 at 4:10 PM ET
Kiora Pharmaceuticals Inc (KPRX) Statistics
Kiora Pharmaceuticals (KPRX) has a market cap of $5.44M. It kept -1276.30% of revenue as net income over the last 12 months. Its share count is up 46.74% from a year earlier.
Total Valuation
| Market Cap | $5.44M |
|---|---|
| Latest price (Nov 17, 2026) | $0.93 |
Key Dates
The next earnings report is expected on Mar 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.9x and 0.4x. Its year-end P/S ranged from 13.7x to 127.6x from 2016 to 2024.
| P/S Ratio | 5.9x |
|---|---|
| P/B Ratio | 0.4x |
| P/TBV Ratio | 0.4x |
Price Statistics
The stock is down 56.94% over 52 weeks and trades 57.92% below its 50-day average.
| Beta (1Y) | 1.39 |
|---|---|
| 52-Week Change | -56.94% |
| 1-Month Change | -60.92% |
| 3-Month Change | -64.23% |
| 6-Month Change | -63.10% |
| 5-Year Change | -99.77% |
| 10-Year Change | -99.98% |
| Total Return (1Y) | -56.94% |
| Total Return (3Y CAGR) | -43.56% |
| Total Return (5Y CAGR) | -71.59% |
| Max Drawdown (1Y) | -67.48% |
| Max Drawdown (3Y) | -87.84% |
| Sharpe Ratio (1Y) | -1.18 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $2.21 |
| 200-Day Average | $2.36 |
| 52-Week Range | $0.95 to $2.91 |
| RSI (14 Days) | 16.3 |
| Average Volume (20 Days) | 74.24K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.91x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 7.91x |
|---|---|
| Quick Ratio | 7.91x |
| Debt / Equity | 0.00x |
| Interest Coverage | 206.49x |
Returns and Efficiency
Return on equity is -83.44% over the last 12 months, against a 5-year average of -94.32%.
| Return on Equity (ROE) | -83.44% |
|---|---|
| Return on Assets (ROA) | -57.04% |
| ROE (5Y Average) | -94.32% |
| ROA (5Y Average) | -53.44% |
| ROIC (5Y Average) | -72.03% |
| Asset Turnover | 0.04x |
| Receivables Turnover | 1.16x |
Scores
KPRX has an Altman Z-Score of -10.61, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -10.61 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $1.00M over the last 12 months.
| Revenue | $1.00M |
|---|---|
| Gross Profit | $989.49K |
| Operating Income | -$13.72M |
| Pretax Income | -$13.25M |
| Net Income | -$12.76M |
| Reported EPS (TTM) | -$2.93 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 68.40% of the $22.37M in total assets.
| Cash and Equivalents | $5.57M |
|---|---|
| Total Debt | $0 |
| Net Cash | $5.57M |
| Net Cash Per Share | $0.88 |
| Working Capital | $17.40M |
| Shareholder Equity | $15.30M |
| Book Value Per Share | $2.43 |
| Tangible Book Value | $13.23M |
| Tangible Book Per Share | $2.10 |
| Total Assets | $22.37M |
| Total Liabilities | $7.08M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $106.99K of capital spending, operating cash flow left -$7.90M of free cash flow.
| Operating Cash Flow | -$7.79M |
|---|---|
| Capital Expenditures | $106.99K |
| Free Cash Flow | -$7.90M |
| FCF Per Share | -$1.79 |
| Depreciation and Amortization | $47.46K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1372.46%.
| Gross Margin | 98.95% |
|---|---|
| Operating Margin | -1372.46% |
| Pretax Margin | -1324.80% |
| Net Margin | -1276.30% |
| FCF Margin | -789.82% |
Dividends and Yields
KPRX does not pay a dividend. Its free cash flow yield is -134.91%.
| FCF Yield | -134.91% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-9 reverse split on Jun 11, 2024.
| Last Split Date | Jun 11, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:9 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About KPRX
What is KPRX's market cap?
Kiora Pharmaceuticals has a market cap of $5.44M.
How many shares of KPRX are outstanding?
Kiora Pharmaceuticals has 6.30M shares outstanding. The count is up 46.74% from a year earlier.
Does KPRX pay a dividend?
No. Kiora Pharmaceuticals does not pay a dividend.
How much debt does KPRX have?
Kiora Pharmaceuticals has $0 of total debt and $5.57M of cash and equivalents, a net cash position of $5.57M.
KPRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors